Immunotherapy revolutionized the treatment of many malignancies. However, many patients fail to respond to immuno-oncology (IO) drugs, although satisfying the accepted clinical criteria for IO treatment.
This stems partially from the very incomplete understanding of the network-level interactions between various cells within the tumor itself, which together determine the fate of the anti-cancer immune responses.
Using a novel, high-resolution method to resolve all the cells that together comprise the tumour micro-environment, we are able to infer important inter-cellular connections that may protect the tumor from an immune assault.
By combining many patient tumor-immune networks, we at Pyxis, can predict IO drug response for many cancer types. Our platform can also suggest alternative treatment routes in cases where the predicted drug response is low, improving the quality of life of oncological patients.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Givat-Ram, Pob 39158, High Tech Village,israel
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Jerusalem
Pyxis Diagnostics Questions
Pyxis Diagnostics's website is https://www.pyxisdiagnostics.com/
Pyxis Diagnostics's LinkedIn profile is https://il.linkedin.com/company/pyxis-dx
Pyxis Diagnostics has
4 employees.
View email and phone details for 4
employees at Pyxis Diagnostics.
Pyxis Diagnostics's industry is
Biotechnology Research
Pyxis Diagnostics's top competitors are
Gilboa Therapeutics,
Tel Aviv Medical Center,
Cytoreason,
Point6 Bio,
Pangea Biomed,
Renewalbio,
Promise Bio,
Curesponse,
Aion Labs,
Transalgae.
Pyxis Diagnostics's categories are Biotechnology Research
Pyxis Diagnostics's founding year is 2020
